Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
NCT06134960Phase 1Recruiting
- Sponsor
- Peking University
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KD-496 in solid tumor, gastric cancer (GC) and pancreatic cancer (PC), sponsored by Peking University. Primary endpoints: Incidence of Treatment Related Adverse Events at 3 months and Dose-Limiting Toxicity Rate at 1 month. Started Nov 2024; status: recruiting.
02
Drugs
KD-496
03
Conditions
solid tumorgastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06134960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134960.